Drug Profile

AZP 3404

Alternative Names: AZP-3404

Latest Information Update: 18 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Maine; University of North Carolina at Chapel Hill
Developer Amolyt Pharma
Class Insulin sensitisers; Obesity therapies; Peptides
Mechanism of Action Insulin-like growth factor II modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Insulin resistance; Obesity

Most Recent Events

15 Jul 2024 Amolyt Pharma has been acquired by AstraZeneca
28 Dec 2022 No recent reports of development identified for preclinical development in Insulin-resistance in France
28 Dec 2022 No recent reports of development identified for preclinical development in Obesity in France

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com